Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Trial details
- Registry ID
- NCT03767348
- Phase
- Phase 2
The FDA approved nivolumab (Opdivo) on 22 Dec 2014.
Drug identity checked against registry records
Also recorded as Opdivo
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348 | Replimune, Inc. | Phase 2 | Active not recruiting | 2028-06Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-12-22Day | nivolumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125554", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["OPDIVO"], "active_ingredients": ["NIVOLUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20141222", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |